M Arbyn

Summary

Affiliation: Scientific Institute of Public Health
Country: Belgium

Publications

  1. ncbi Cervical cancer screening programmes and policies in 18 European countries
    A Anttila
    The Finnish Cancer Registry, Helsinki, Finland
    Br J Cancer 91:935-41. 2004
  2. ncbi Visual inspection with acetic acid as a cervical cancer test: accuracy validated using latent class analysis
    Lynne Gaffikin
    Cervical Cancer Prevention Program, JHPIEGO, Baltimore, USA
    BMC Med Res Methodol 7:36. 2007
  3. ncbi Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence
    M Arbyn
    Scientific Institute of Public Health, Brussels, Belgium
    Gynecol Oncol 99:S7-11. 2005
  4. ncbi European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology
    M Arbyn
    Scientific Institute of Public Health, Brussels, Belgium, and European Cancer Network, IARC, Lyon, France
    Cytopathology 18:133-9. 2007
  5. ncbi Burden of cervical cancer in Europe: estimates for 2004
    M Arbyn
    Scientific Institute of Public Health, Brussels, Belgium
    Ann Oncol 18:1708-15. 2007
  6. ncbi Adverse obstetrical outcomes after treatment of precancerous cervical lesions: a Belgian multicentre study
    C Simoens
    Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
    BJOG 119:1247-55. 2012
  7. ncbi Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis
    M Arbyn
    Scientific Institute of Public Health, Brussels, Belgium
    BMJ 337:a1284. 2008
  8. ncbi Introduction of human papillomavirus vaccination in Belgium, Luxembourg and the Netherlands
    M Arbyn
    Belgian Cancer Center Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium marc arbyn wiv isp be
    Gynecol Obstet Invest 70:224-32. 2010
  9. ncbi Cervical cancer screening in Belgium
    M Arbyn
    Scientific Institute of Public Health, J Wytsmanstreet 14, B 1050, Belgium
    Eur J Cancer 36:2191-7. 2000
  10. ncbi Worldwide burden of cervical cancer in 2008
    M Arbyn
    Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
    Ann Oncol 22:2675-86. 2011

Detail Information

Publications26

  1. ncbi Cervical cancer screening programmes and policies in 18 European countries
    A Anttila
    The Finnish Cancer Registry, Helsinki, Finland
    Br J Cancer 91:935-41. 2004
    ..Our survey indicated that the recommendations as currently given are met in only few European countries. Health authorities need to consider stronger measures and incentives than those laid out in the current set of recommendations...
  2. ncbi Visual inspection with acetic acid as a cervical cancer test: accuracy validated using latent class analysis
    Lynne Gaffikin
    Cervical Cancer Prevention Program, JHPIEGO, Baltimore, USA
    BMC Med Res Methodol 7:36. 2007
    ..The data were originally collected at peri-urban health clinics in Zimbabwe...
  3. ncbi Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence
    M Arbyn
    Scientific Institute of Public Health, Brussels, Belgium
    Gynecol Oncol 99:S7-11. 2005
    ..By triage, those women can be identified who need referral for diagnostic exploration with colposcopy and/or biopsy...
  4. ncbi European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology
    M Arbyn
    Scientific Institute of Public Health, Brussels, Belgium, and European Cancer Network, IARC, Lyon, France
    Cytopathology 18:133-9. 2007
    ..Subsequently, the slide or vial and the completed request form are sent to the laboratory for cytological interpretation...
  5. ncbi Burden of cervical cancer in Europe: estimates for 2004
    M Arbyn
    Scientific Institute of Public Health, Brussels, Belgium
    Ann Oncol 18:1708-15. 2007
    ..The European Commission should maintain cervical cancer control in future action plans and increase support to the most affected member states...
  6. ncbi Adverse obstetrical outcomes after treatment of precancerous cervical lesions: a Belgian multicentre study
    C Simoens
    Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
    BJOG 119:1247-55. 2012
    ..To assess the impact of cervical intraepithelial neoplasia (CIN) treatment on the risk of (spontaneous) preterm delivery (PD) and small for gestational age (SGA) at birth...
  7. ncbi Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis
    M Arbyn
    Scientific Institute of Public Health, Brussels, Belgium
    BMJ 337:a1284. 2008
    ..To assess the relative risk of perinatal mortality, severe preterm delivery, and low birth weight associated with previous treatment for precursors of cervical cancer...
  8. ncbi Introduction of human papillomavirus vaccination in Belgium, Luxembourg and the Netherlands
    M Arbyn
    Belgian Cancer Center Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium marc arbyn wiv isp be
    Gynecol Obstet Invest 70:224-32. 2010
    ..To document progress with human papillomavirus (HPV) vaccine introduction in three closely related European countries, one with organized (the Netherlands) and two with opportunistic cervical cancer screening (Belgium and Luxembourg)...
  9. ncbi Cervical cancer screening in Belgium
    M Arbyn
    Scientific Institute of Public Health, J Wytsmanstreet 14, B 1050, Belgium
    Eur J Cancer 36:2191-7. 2000
    ..The coverage is lower in the Walloon and the Capital Region. Rationalisation of the policy regarding cancer screening involving all concerned authorities of the country is necessary...
  10. ncbi Worldwide burden of cervical cancer in 2008
    M Arbyn
    Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
    Ann Oncol 22:2675-86. 2011
    ..Up-to-date and reliable data are needed to assess impact of existing preventive measures and to define priorities for the future...
  11. ncbi European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document
    M Arbyn
    Unit of Cancer Epidemiology Belgian Cancer Center, Scientific Institute of Public Health, Brussels, Belgium
    Ann Oncol 21:448-58. 2010
    ....
  12. ncbi Monitoring of human papillomavirus vaccination
    J Dillner
    WHO HPV LabNet Global Reference Laboratory at Department of Clinical Microbiology, University Hospital, Malmo
    Clin Exp Immunol 163:17-25. 2011
    ..Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control...
  13. ncbi Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women
    C E Depuydt
    Laboratory for Clinical Pathology Labo RIATOL, Antwerp, Belgium
    Br J Cancer 88:560-6. 2003
    ..7%). In Flanders, HSIL was most often associated with HPV types 16, 33, 35, 31, 18 and 51. Using thin-layer liquid-based cytology and PCR to detect HPV, it is feasible to screen large numbers of women...
  14. ncbi Management of minor cervical cytological abnormalities: a systematic review and a meta-analysis of the literature
    M Kyrgiou
    Department of Obstetrics and Gynaecology, Victoria Hospital, Blackpool FY3 8NR, UK
    Cancer Treat Rev 33:514-20. 2007
    ..However, protracted attendance for cytological follow-up decreases with time and might put some women at risk of developing invasive disease. The aim of this review was to assess management options for women with minor cervical disease...
  15. ncbi European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology
    A Herbert
    Guy s and St Thomas Hospital NHS Foundation Trust, London, UK
    Cytopathology 18:213-9. 2007
    ..These guidelines should allow European countries to adapt their terminology in such a way as to make their screening programmes comparable with each other as well as with programmes elsewhere in the world...
  16. ncbi Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer
    W A A Tjalma
    Department of Gynecology and Gynecologic Oncology, University Hospital Antwerp, University Antwerp, 2650 Edegem, Antwerp, Belgium
    Int J Gynecol Cancer 14:751-61. 2004
    ..This article will address the status of recently terminated phase II and currently running phase III trials with prophylactic HPV vaccines...
  17. ncbi Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination
    J Dillner
    WHO Global Reference Laboratory for HPV Diagnosis and Control, Department of Clinical Microbiology, University Hospital, SE 20502 Malmo, Sweden
    Clin Exp Immunol 148:199-207. 2007
    ..Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most (cost-)effective strategies for cancer control...
  18. ncbi European guidelines for quality assurance in cervical cancer screening: recommendations for cytology laboratories
    H G Wiener
    Institute of Clinical Pathology, University Vienna, Austria
    Cytopathology 18:67-78. 2007
    ..The guidelines are extensively referenced and as far as possible the recommendations are evidence-based...
  19. ncbi Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis
    M Kyrgiou
    Department of Obstetrics and Gynaecology, Central Lancashire Teaching Hospitals, Preston, UK
    Lancet 367:489-98. 2006
    ..In a meta-analysis, we investigated the effect of these procedures on subsequent fertility and pregnancy outcomes...
  20. ncbi Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation
    J Verguts
    Department of Obstetrics and Gynecology, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium
    BJOG 113:1303-7. 2006
    ....
  21. ncbi The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach
    M Kyrgiou
    Department of Obstetrics and Gynaecology, Hammersmith Hospital, Queen Charlotte's and Chelsea Hospital, London W12 0HS, UK
    Cancer Treat Rev 32:516-23. 2006
    ..Existing guidelines should probably be updated incorporating the new information emerged from recently published work...
  22. ncbi Ovarian cancer screening
    M Kyrgiou
    Department of Obstetrics and Gynaecology, Hammersmith Hospital, Queen Charlotte's and Chelsea Hospital, London, W12 OHS
    Anticancer Res 26:4793-801. 2006
    ..However, the conclusive end-point that would provide the acceptable level of evidence for the introduction of screening should be a reduction in mortality. Up-to-date, there is no such evidence to justify this...
  23. ncbi Cervical cytology biobanking: quality of DNA from archival cervical Pap-stained smears
    G A V Boulet
    Applied Molecular Biology Research AMBIOR, Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium
    J Clin Pathol 61:637-41. 2008
    ..This study evaluates three commercial isolation methods and one digestion procedure for their ability to obtain DNA suitable for PCR from fixed and stained Pap smears...
  24. ncbi Why CIN3 and CIN2 should be distinguished on histological reports
    A Herbert
    Cytopathology 19:63-4. 2008
  25. ncbi Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004
    M Arbyn
    Ann Oncol 18:1423-5. 2007
  26. ncbi Rapid pre-screening of Pap smears in quality control: an Italian experience
    A Placidi
    Cytopathology 15:121-3. 2004